Dermata Therapeutics, Inc.

What they do

Dermata historically developed XYNGARI (DMT310), a Phase 3 acne candidate, but in September 2025 shifted strategy to commercialize science-backed skincare products. The company's hero ingredient is Spongilla lacustris, and it plans to launch its first cosmetic product, Tome Foundational Treatment, in August 2026, followed by an OTC acne treatment.

Revenue drivers

• Tome Foundational Treatment (DTC cosmetic) — First commercial product, expected to launch August 25, 2026; no revenue generated to date.
• OTC acne product (future) — Second DTC product, a once-weekly OTC topical acne treatment, expected to launch after the foundational treatment; no revenue yet.
• Future product line (planned) — Management plans to expand the Tome brand with additional products targeting specific skin conditions; no details or revenue projections provided.

Recent performance

For Q2 2026, Dermata had $4.4 million in cash and cash equivalents, down from $7.5 million at year-end 2025. Cash used in operations was $4.9 million for the six months ended June 30, 2026, with $0.1 million used in investing activities, offset by $1.9 million in ATM financing proceeds. Research and development expenses fell to $0.2 million in Q2 2026 from $0.6 million in Q2 2025, reflecting a shift to pre-commercial launch activities. The company has incurred net losses for every year presented: $-7.9M (2021), $-9.6M (2022), $-7.8M (2023), $-12.3M (2024), and $-7.6M (2025).

Strategy

Management pivoted from prescription development to DTC and B2B skincare, aiming for faster commercialization and lower regulatory burden. The company plans to leverage its clinical dermatology expertise and the Spongilla lacustris ingredient to build a product line addressing acne, psoriasis, and rosacea. Priorities include launching Tome Foundational Treatment, building the Tome brand through social media and trade shows, and developing a second OTC acne product. The company intends to use direct consumer relationships to gather data and expand its portfolio over time.

Risks

• No operating history as a commercial company — Dermata has never launched a commercial product and lacks experience in manufacturing, marketing, and distribution for consumer skincare.
• Capital constraints — With $4.4 million in cash as of June 30, 2026, management expects funding to last only into Q4 2026, requiring additional capital soon.
• Regulatory and compliance risk — OTC formulations must comply with FDA OTC monographs, labeling rules, and cGMP standards; failure could delay launch or require reformulation.
• Competition and consumer acceptance — The skincare market is highly competitive, and positive clinical data may not translate into consumer acceptance or commercial performance.

Outlook

Management expects to launch Tome Foundational Treatment on August 25, 2026, and to follow with an OTC acne product later. The company plans to continue building the Tome brand and expand its product portfolio. Cash runway is projected only into Q4 2026, so additional financing is likely needed.